Gland Pharma
Gland Pharma Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
4 of 4 strong
Not discussed on this call: order book.
The short version
Gland Pharma targets a 15% CAGR over the next 4-5 years; new contracts could push growth closer to 20% annually. Gland Pharma expects revenue growth at a CAGR of approximately 20%-25% over the next 4 years.
From Gland Pharma's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Gland Pharma targets a 15% CAGR over the next 4-5 years; new contracts could push growth closer to 20% annually.
- U.S. revenues currently about USD 110-120 million, expected to grow faster than the market (3-4%) due to new product launches and operational efficiencies.
- Complex product portfolio contribution is expected to increase post FY29, potentially taking a larger share of U.S. business revenue.
- CDMO business aims to comprise around 30% of consolidated revenues in the near term, with higher margins than traditional IP-led business.
- Bag line and ophthalmic products capacity expansions pending FDA approvals may accelerate growth beyond 15% in the current fiscal year.
- New product launches over the next 3-4 years are expected to drive growth, maintaining momentum beyond current base business.
- Constant currency growth guidance for the current year is around 15%, with potential to exceed 15% if new lines are approved timely.
Profitability & Margins
See what Gland Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ongoing execution of a recently announced INR 2,000 crores capital expenditure program.
- Q1 FY27 capex of INR 1,132 million towards capacity expansion, capability enhancements, infrastructure additions supporting CDMO and fill/finish platforms.
- Immediate INR 165 crores capex for installing an isolator line in oncology plant (to be installed by January).
- Capex towards vial, ophthalmic, BFS lines, and liposome products at India sites on track.
- Capacity expansion projects approved and prioritized to meet growing CDMO collaboration demand.
- Growth capex at Cenexi for adding a new block underway.
- Neuland collaboration: capex for building an API block has started.
- Projected INR 550 crores capex spend in the current year scaling up with further brownfield expansions.
- Focus on brownfield or greenfield expansions to support volume growth.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gland Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Current order book size mentioned is around INR600 crore to INR700 crore, expected to increase further.
- New contracts recently signed will contribute about 12% to current revenue, supporting a 20% growth over the next 4 years.
- The company is actively working on both brownfield and greenfield expansions to support volume growth.
- There is ongoing negotiation/discussion with partners for additional contracts, expected to provide more clarity on growth and order book by next quarter.
- CDMO business currently contributes about 50% of revenue, with a near-term target to reach 30% on a consolidated basis.
- Larger contracts, including one expected in FY29, will ramp up the order book and revenue significantly.
- Cenexi subsidiary turnaround and new product launches are also expected to add to order book and growth momentum.
Gland Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.7K Cr, net profit ₹367 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gland Pharma's management said in earlier quarters
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Gland Pharma Q1 FY27 results?
Gland Pharma targets a 15% CAGR over the next 4-5 years; new contracts could push growth closer to 20% annually. Gland Pharma expects revenue growth at a CAGR of approximately 20%-25% over the next 4 years.
What is Gland Pharma share price analysis?
Gland Pharma currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 40.6 with a market cap of ₹46,509 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gland Pharma planning capital expenditure?
Ongoing execution of a recently announced INR 2,000 crores capital expenditure program.
Keep Gland Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.